LICENSING & TRADEMARK INTEGRITY

Dezawa MuseCells® is a registered trademark, and Muse Cell Innovations® is the exclusive global licensor of this cellular platform.Only official licensees are granted access to validated protocols, safety data, and platform-level implementation support.All procedures for sourcing, handling, and verifying Dezawa MuseCells® are proprietary and delivered only to authorized partners.We make no guarantees regarding the handling, quality, or safety of cells outside of the licensed supply chain. Use of the Dezawa MuseCells® name or likeness without license is prohibited.Accept no substitutes. Work only with verified licensees. Request Licensing information →

Muse Cell Innovations® does not promote or offer direct-to-consumer treatments.All clinical use of Dezawa MuseCells® must occur under licensed, ethics-reviewed, and jurisdictionally approved frameworks.This site is intended for institutional, clinical, and scientific audiences only.All published information utilizes Dezawa MuseCells® that are manufactured in accordance with MCIs patented processes.

Intranasally administered muse cells attenuate neurodegeneration in Parkinson’s disease

MENU

Intranasally administered muse cells attenuate neurodegeneration in Parkinson’s disease

LATEST ON DEZAWA MUSECELLS®

Cardiovascular, Clinical Trials

Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis

Other, Publications

Why Do Muse Stem Cells Present an Enduring Stress Capacity? Hints from a Comparative Proteome Analysis

Clinical Trials, Other

Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial

Intranasally administered muse cells attenuate neurodegeneration in Parkinson’s disease

Cardiovascular, Clinical Trials

Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis

Other, Publications

Why Do Muse Stem Cells Present an Enduring Stress Capacity? Hints from a Comparative Proteome Analysis

Clinical Trials, Other

Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial

Request Licensing Information